Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orchid Pharma's gross profit for the
three
months ended in Jun. 2026 was $10.5 Mil. Orchid Pharma's gross profit for the trailing twelve months (TTM) ended in Jun. 2026 was $33.8 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Orchid Pharma's gross profit for the
three
months ended in Jun. 2026 was $10.5 Mil. Orchid Pharma's Revenue for the
three
months ended in Jun. 2026 was $32.0 Mil. Therefore, Orchid Pharma's Gross Margin % for the quarter that ended in Jun. 2026 was 32.83%.
Orchid Pharma had a gross margin of 32.83% for the quarter that ended in Jun. 2026 => Competition eroding margins
During the past 13 years, the highestGross Margin % of Orchid Pharma was 53.70%. The lowest was 33.02%. And the median was 43.53%.
Warning Sign:
Orchid Pharma Ltd gross margin has been in long-term decline. The average rate of decline per year is -4.2%.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Orchid Pharma had a gross margin of 32.83% for the quarter that ended in Jun. 2026 => Competition eroding margins
Orchid Pharma Gross Profit Related Terms
Orchid Pharma Gross Profit Historical Data
* Premium members only.
The historical data trend for Orchid Pharma's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Orchid Pharma's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orchid Pharma Gross Profit vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orchid Pharma's Gross Profit distribution charts can be found below:
* The bar in red indicates where Orchid Pharma's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $33.8 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Orchid Pharma (LUX:ORCHP) has a Gross Profit of $33.8 Mil as of Jun. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Orchid Pharma and its competitors.
Is Orchid Pharma's Gross Profit too high?
Orchid Pharma's current Gross Profit is $33.8 Mil. Overall, Orchid Pharma has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Orchid Pharma's Gross Profit compare to ZTS?
Orchid Pharma's Gross Profit of $33.8 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Drug Manufacturers company?
A good Gross Profit depends on the Drug Manufacturers industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Orchid Pharma and its competitors. Orchid Pharma's current Gross Profit is $33.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orchid Pharma stock overvalued right now?
Orchid Pharma (LUX:ORCHP) has a current Gross Profit of $33.8 Mil. The stock's GF Value™ is $5.03, compared to a current price of $5.45 — trading 8.3% above its estimated fair value. The current Gross Profit is $33.8 Mil. Orchid Pharma's overall GF Score™ is 60/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Orchid Pharma (LUX:ORCHP), the current Gross Profit is $33.8 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orchid Pharma (LUX:ORCHP) Overvalued in 2026?
Based on GuruFocus' analysis, Orchid Pharma stock appears to be overvalued.
The current stock price of $5.45 is trading 8.3% above its estimated GF Value™ of $5.03.
Key valuation signals for LUX:ORCHP:
Gross Profit: $33.8 Mil
GF Value™: $5.03 vs. price of $5.45 (8.3% above fair value)
No single metric tells the full story. See the LUX:ORCHP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orchid Pharma Ltd is involved in the development, manufacturing, and marketing of diverse bulk actives, formulations, and nutraceuticals. The company operates in one business segment, which is Pharmaceuticals, in which the company derives its maximum sales through Active Pharmaceutical Ingredients. It produces various products such as tablets, injectables, and APIs for cardiovascular, anti-diabetic, neuropsychiatry, veterinary, non-antibiotic, and cephalosporins. The products are grouped under formulations and active pharmaceutical ingredients. Geographically, the company generates maximum revenue from the export of its products to international markets like the United States, Canada, Europe, Japan, Australia, and China etc., and the rest from its business in India.
60GF Score
Get the complete analysis for LUX:ORCHP
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUX:ORCHP has been successfully added to your 
